A multi-center, non-interventional, prospective study of durvalumab in unresectable locally advanced NSCLC in routine clinical practice in Russia

Trial Identifier: D4194R00027
Sponsor: AstraZeneca
Start Date: May 2022
Primary Completion Date: November 2026
Study Completion Date: November 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russian Federation Arkhangelsk, Russian Federation
Russian Federation Chelyabinsk, Russian Federation
Russian Federation Ekaterinburg, Russian Federation
Russian Federation Grozniy, Russian Federation
Russian Federation Irkutsk, Russian Federation
Russian Federation Khanty-Mansiysk, Russian Federation
Russian Federation Kostroma, Russian Federation
Russian Federation Krasnodar, Russian Federation
Russian Federation Krasnoyarsk, Russian Federation
Russian Federation Murmansk, Russian Federation
Russian Federation Nizhniy Novgorod, Russian Federation
Russian Federation Perm, Russian Federation
Russian Federation Saint Petersburg, Russian Federation
Russian Federation Sochi, Russian Federation
Russian Federation Surgut, Russian Federation
Russian Federation Tomsk, Russian Federation
Russian Federation Ufa, Russian Federation
Russian Federation Vologda, Russian Federation
Russian Federation Yaroslavl, Russian Federation
Russian Federation Yuzhno-Sakhalinsk, Russian Federation